Becton Dickinson and Co vs Sibanye Stillwater Ltd — how do they compare? Becton Dickinson and Co trades at $182.41 (market cap $49.41B), while Sibanye Stillwater Ltd trades at $10.75 (market cap $7.54B). The key difference: Becton Dickinson and Co is far larger — about 6.6× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (2.93%). Which is the better fit depends on your goals.
| BDX | SBSW | |
|---|---|---|
Market Cap | $49.41B | $7.54B |
Sector | Health | Basic Materials |
52-Week High | $185.39 | $21.12 |
52-Week Low | $138.62 | $7.27 |
Enterprise Value | $65.51B | $9.19B |
Dividend Yield | 2.32% | 2.93% |
Signals from Pluang's Aura AI — not financial advice
BDX trades at $180.64, up 0.56% today, near its consensus price target of $183. The stock shows bullish technical signals with strong moving averages and recent earnings beats in Q2 2026. Revenue growth is steady, with Q3 2026 reaching $5 billion, though margins face pressure from tariffs. The company maintains a Dividend Aristocrat status with consistent payouts.
Outlook is cautiously optimistic with analyst consensus leaning buy, but risks include margin compression and debt levels. The stock offers stability through dividends and sector resilience, yet investors should monitor earnings sustainability and competitive threats in the medical technology space.
Sibanye Stillwater (SBSW) trades at $10.74, up 0.66% with a bullish technical signal. The company shows mixed fundamentals with a negative net income margin of -3.99% but strong operating cash flow of $10.11B in 2024. Recent earnings misses and declining revenue since 2021 highlight challenges, though analyst consensus remains positive with a $14.25 price target. Technical indicators show overbought RSI levels but strong moving average support.
SBSW presents a high-risk opportunity with significant upside potential if management executes on debt reduction and operational improvements. Key risks include persistent negative profitability, commodity price volatility, and execution challenges. The stock's deep value metrics (P/E of 4.76) contrast with operational headwinds, requiring careful monitoring of quarterly execution against guidance.
Trailing returns across standard periods
Latest headlines on both assets
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →